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Abstract Th17 cells are implicated in human autoimmune
diseases, such as rheumatoid arthritis (RA), although it has not
been established whether this persistent destructive arthritis is
driven by Th1 and/or Th17 cells. Interleukin-17A (IL-17A)
contributes to the pathogenesis of arthritis as has been shown
in several experimental arthritis models. Importantly, recent
data from first clinical trials with anti-IL-17A antibody
treatment in psoriatic arthritis patients and RA patients looks
promising. This review summarizes the findings about the role
of Th17 cells in arthritis and discusses the impact of the
different Th17 cytokines in the pathogenesis of this disease.
However, further studies are needed to unravel the interplay
between IL-17A and other Th17 cytokines such as IL-17F, IL-
22, and IL-21 in the pathoimmunological process of this
crippling disease, in particular, whether regulating Th17 cell
activity or specific combinations of Th17 cytokines will have
additional value compared to neutralizing IL-17A activity
alone. Moreover, tumor necrosis factor-positive Th17 cells
are discussed as potential dangerous cells in driving
persistent arthritis in human early RA.
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Is rheumatoid arthritis a Th1- and/or Th17-driven
disease?
Rheumatoid arthritis (RA) is characterized by synovial inflam-
mation and destruction of joint cartilage and bone mediated by
persistent synthesis of proinflammatory cytokines and matrix
metalloproteinases (MMP) [4]. T cell activation and migration
occurs as an early consequence of RA, and these cells adopt a
proinflammatory phenotype. Classically, autoimmune diseases
such as RA were thought to be a Th1- and not a Th2-
associated disorder [21]. At present, it is unclear whether RA
is a Th1- and/or Th17-mediated disease [52] (Fig. 1). It has
been shown that interleukin-17A (IL-17A) is produced by
some proinflammatory Th1/Th0 cells isolated from synovial
membranes and from synovial fluid of RA patients. In joints
of patients with established RA, predominantly, Th1 but not
Th17 cells were observed [1]. We detected a relatively high
percentage of IL-17A-producing CCR6+ memory T cells in
peripheral blood mononuclear cell (PBMC) from treatment-
naïve early RA patients [14] (Van Hamburg et al., unpublished
observations). Of note, the Th1 interferon (IFN)-gamma and
the Th17 IL-17 cytokines are often coexpressed in human
memory CD4+CD45+RO+ T cells from treatment-naïve early
RA patients [14].
Although the levels of IL-17A in sera of RA patients is
hard to detect, elevated levels of this Tcell cytokine have been
demonstrated in synovial fluid of these patients [10, 41, 100].
In line with these enhance IL-17A levels in the joint, IL-
17A-producing CCR6+ memory T cells have been identified
in synovial fluid of RA patients [25].
Similar as for the human situation, in the autoimmune
collagen-induced arthritis (CIA) model, the mouse model for
RA, it is hard to detect IL-17A levels in the serum of arthritic
mice. In contrast, elevated levels of IL-17A have been found
in inflamed synovium [53]. IL-17A blocking experiments
have shown the importance of this T cell cytokine as
proinflammatory in the pathogenesis of CIA [8, 53, 54].
Furthermore, as in human RA, IL-17 plays an important role
in the additive/synergistic effects induced together with
tumor necrosis factor (TNF) and IL-1, two key cytokines in
destructive arthritis [55, 62].
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In CIA, it is clear that the IL-23/Th17 axis is critical for
the development of autoimmune arthritis. Mice that were
deficient for IL-23 were completely protected against the
development of CIA. Interestingly, these IL-23-deficient
mice had no IL-17+ CD4 T cells but normal antigen-
specific IFN-gamma-producing Th1 cells [65]. These data
show that IL-17-producing CD4+ T cells but not IFN-
gamma-producing CD4+ T cells are critical for the
initiation of CIA. In line with these results, we found in
the T cell-dependent antigen-induced mono-arthritis (AIA)
model that lack of IL-23 did not prevent the onset of AIA
but protect against progression of joint inflammation into
a destructive synovitis [15]. Lower proportion of IL-17-
positive T cell receptor gamma delta and IL-17-positive
CD4+ T cells was noted in the spleen, lymph nodes, and
inflamed synovium in these IL-23-deficient arthritic mice.
Interestingly, although mono-arthritis induction in IL-23-
deficient mice did not result in a lower proportion of IFN-g-
positive CD4+ T cells in the spleen and lymph node, a
lower proportion of these cell was detected in the target
organ, the joint [15]. Therefore, IL-23 could be required to
promote Th1 and Th17 effector responses, especially at
the target organ/tissue of inflammation, and further studies
are needed to understand this phenomenon.
Are Th17 cells found in different arthropathies?
Although relatively high numbers of Th17 cells have been
shown in PBMC from treatment-naïve early RA patients
[14] (Van Hamburg JP et al., unpublished observations), the
proportion of these cells in PBMC and synovial-fluid
mononuclear cells in established RA varies between no
Th17 to low Th17 cells (Table 1). Yamada et al. [96]
showed that IL-17-positive cells were detected in CD45RO+
CD4 T cells in RA, and most IL-17 positive cells produced
neither IFN-gamma nor IL-4, but TNF [96]. The frequency
of Th17 cells was neither increased in RA nor correlated
with the DAS28 disease activity score. Unexpectedly, the
frequency of Th17 cells was significantly decreased in the
joints compared with PBMC of the same patients with RA,
whereas Th1 cells were more abundant in the joints than in
PBMC in these established RA patients [96]. Increased
levels of IL-17A, IL-6, TGF-beta, and IFN-gamma
concentrations in sera and synovial fluid of reactive
arthritis (ReA) and undifferentiated spondyloarthropathy
(uSpA) compared to RA have been shown, suggesting that
Th1 and Th17 cells could be the major agents in
inflammation in ReA/uSpA [81] (Table 1). Jandus et al.
[34] found increased numbers of circulating Th17 cells in
the peripheral blood of patients with seronegative spondylar-
thritides (psoriatic arthritis and ankylosing spondylitis), but
not in patients with RA (Table 1). In addition, Th17 cells
from the spondylarthritis patients showed advanced differ-
entiation and were polyfunctional in terms of T cell receptor-
driven cytokine production [34].
Subclinical gut inflammation is common in spondylar-
thritis. A strong and significant upregulation of IL-23p19
transcript was found in the terminal ileum in patients with
AS and patients with Crohn's disease (CD). IL-23 was
abundantly produced by infiltrating monocyte-like cells in
inflamed mucosa from AS and CD patients [12]. Notably,
Paneth cells were identified as a major source of IL-23 in
patients with AS, patients with CD, and normal controls
[12]. It has been shown that Paneth cells can also be a
source of IL-17A in a TNF-induced experimental shock
model in mice [84]. However, unlike CD, in AS patients,
IL-23 was not associated with upregulation of IL-17 and
the IL-17-inducing cytokines IL-6 and IL-1beta, indicating
that overexpression of IL-23 but not IL-17 is a pivotal
feature if subclinical gut inflammation in AS [12].
In patients with systemic sclerosis (SSc) increased IL-
17A messenger RNAwas expressed in unstimulated PBMC
and lymphocytes from the skin and lungs of SSc patients,
but not in similar samples from patients with systemic lupus
erythematosus (SLE), polymyositis/dermatomyositis, or
from healthy donors (Table 1). IL-17 levels were also
increased in the serum of SSc patients, but not in that of
SLE patients or healthy donors. IL-17 overexpression was
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Fig. 1 Schematic overview of the (potential) role of Th1 and Th17
cells in RA
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significantly related to the early stage of SSc, but not to
other clinical features of SSc [45] Furthermore, Radstake et
al. showed that CD4, CD45RA, and CD45RO cells from
SSc patients highly express the IL-23 receptor, which was
associated with high IL-17 expression as well [75]. In
contrast, IFN-gamma and TGF-beta were selectively upre-
gulated in subsets of SSc patients. In addition, circulating
levels of IL-17-inducing cytokines IL-6, IL-23, and IL-
1alpha were increased in all or subsets of SSc patients. The
combination of IL-17, IFN-gamma, and TGF-beta levels in
CD45RO and CD45RA cells from SSc patients can be
useful to distinguish between limited cutaneous SSc, early
diffuse cutaneous SSc, or late diffuse cutaneous SSc [75].
Human data implicating IL-17 in lupus has become
available [82, 94]. In contrast, some evidence argues
against a role for IL-17 in human lupus [45, 61] (Table 1).
In the mouse model for lupus-like autoimmunity, the BXD2
mouse model, a dramatic upregulation of serum IL-17 and
numbers of Th17 cells have been demonstrated [27]. BXD2
mice form spontaneous germinal centers which was IL-17-
dependent, and treatment with IL-17 promoted the secretion
of both IgM and IgG autoantibodies which was reduced by
crossing BXD2 mice to IL-17R KO mice [27]. A potential
role for IL-17-producing T cells has been shown in Ets-1
knockout mice, another mouse model of lupus [63, 90] and
in the spontaneous mouse model of lupus, the New Zealand
Black (NZB)×SWR F1 cross (SNF1 mice) [36]. These
studies reveal that there is increasing evidence in both
humans and mouse models that IL-17-producing cells play
a role in SLE progression.
Human Lyme arthritis is caused by Borrelia burgdorferi
and is characterized by an inflammatory infiltrate that
consists mainly of neutrophils and T cells. B. burgdorferi,
Mycobacterium tuberculosis, and synthetic lipopeptides
derived from B. burgdorferi outer surface lipoproteins
induced IL-17 expression in both murine and human Th
Table 1 The IL-23/IL-17 axis in different arthropathies
Arthropathy Systemic At site of
inflammation
Reference
Early RA Th17: IL-17A, IL-17F, IL-22, TNF ND [14]
Th1: IFN-gamma
Established RA Th17 Th17↓ [96]
Th1 Th1↑
No Th17 [34]
ReA/undifferentiated spondylarthropathy IL-17A IL-17A [81]
IL-6 IL-6
TGF-beta TGF-beta
IFN-gamma IFN-gamma
Seronegative spondylarthritides: psoriatic
arthritis and ankylosing spondylitis
Th17 ND [34]
Systemic sclerosis IL-17A mRNA, IL-17A levels ND [45, 75]
CD4, CD45RA, CD45RO: IL-23R+
and Il-17A+
IL-6
IL-23
IL-alpha
SLE No IL-17A ND [45]
No IL-17A [61]
IL-17A [94]
IL-17A [82]
Lyme arthritis ND IL-17+ cells [13]
Wegener's granulomatosis Th17 ND [3]
Th2
Sjogren's syndrome IL-17A/IL-23 IL-17+ [68]
IL-23+
IL-18 [79]
Th17
Juvenile idiopathic arthritis IL-17+ T cells IL-17+ T cells↑ [69]
ND not determined
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cells [30]. The IL-17-producing Th population is char-
acterized by the coexpression of the proinflammatory
cytokines IL-17, TNF, and granulocyte-macrophage
colony-stimulating factor [30]. Anti-NapA (neutrophil-
activating protein A of B. burgdorferi) antibodies were
found in 48% of the patients with Lyme arthritis but were
undetectable in the healthy controls [13]. T cells from the
synovial fluid of patients with Lyme arthritis produced IL-
17 in response to NapA. Moreover, NapA was able to
induce the expression of IL-23 in neutrophils and mono-
cytes, as well as the expression of IL-6, IL-1beta, and TGF-
beta in monocytes via Toll-like receptor 2 [13]. Therefore,
NapA of B. burgdorferi is able to elicit a synovial fluid
Th17 cell response that might play a crucial role in the
pathogenesis of Lyme arthritis [13] (Table 1). In addition,
IL-23 is required for the development of arthritis in mice
vaccinated and challenged with Borrelia species [42].
In patients with Wegener's granulomatosis (WG) in
remission, the percentage of Th17 cells and Th2 cells
within the activated CD69+, CD4+ T cell population were
significantly increased, while no difference was found in
Th1 cells compared with the percentage in healthy controls
(Table 1). Increased percentages of Th17 cells in response
to tetanus toxoid and staphylococcal enterotoxin B were
found both in antineutrophil cytoplasmic antibody
(ANCA)-positive and in ANCA-negative patients, while
an increased frequency of PR3-specific Th17 cells was
restricted to ANCA-positive patients. Therefore, a skewed
Th17 response found in ANCA-positive WG patients
following stimulation with the autoantigen PR3 suggests
that IL-17 is involved in disease pathogenesis and could
constitute a new therapeutic target for WG [3].
Also, in Sjogren's syndrome (SS), an upregulation has
been shown of the Th17/IL-23 system at the time of disease
[68] (Table 1). Salivary gland biopsy specimens from SS
patients revealed strong positive staining for both IL-17 and
IL-23 within lymphocytic foci and diffuse staining on
epithelial tissues. In sera and saliva from SS patients, IL-17
and IL-6 were present at varying levels [68].
In addition, IL-18 and Th17 cells detected in the salivary
glands in SS patients are associated with the pathogenesis
of SS in the salivary glands [79].
IL-17+ T cells were also detected in the joints of children
with juvenile idiopathic arthritis (JIA), and these cells were
enriched in the joint compared to the blood of JIA patients
[69] (Table 1). Of note, IL-17+ T cell numbers were higher
in patients with extended oligoarthritis, the more severe
subtype of JIA, as compared with patients with persistent
oligoarthritis, the milder subtype [69]. Within the joint,
there was an inverse relationship between IL-17+ T cells
and FoxP3+ Treg cells [69].
These studies suggest that IL-17+ T cells contribute to
the pathogenesis of different arthropathies and that the stage
of the disease and the site of expression might be important
for the role of these IL-17+ T cells in the pathogenesis of
the disease. Furthermore, the balance between, on one
hand, Th17 and Th1 and, the other hand, Th17 and Treg
may be critical in disease outcome.
What is the functional role of Th17 and Th1 cells
in arthritis?
Th17 cells have been detected in different arthropathies, but
their functional role in the human disease has not been
established. Both Th1 and Th17 cells have been recognized in
RA; however, it remains unclear whether Th1 and/or Th17
cells drive disease chronicity [52]. In experimental arthritis
models, Th17 cells have been recognized as important
contributors to the inflammatory processes [52, 55], and
preferential recruitment of CCR6-expressing Th17 cells to
inflamed joints via CCL20 in RA and its animal model has
been shown [25]. However, in experimental autoimmune
encephalitis (EAE) and experimental autoimmune uveoreti-
nitis models, evidence also suggest the potential of Th1 cells
as pathogenic mediators [44, 57]. In arthritis, both Th17- and
Th1-dependent experimental models have been described
[19, 25, 65, 67, 88]. Th17-dependent models can be induced
by a specific antigen with complete Freund's adjuvant, but
also Th17-dependent spontaneous arthritis models were
reported [25, 65, 67, 88]. On the other hand, the develop-
ment of proteoglycan-induced arthritis has been shown to be
IL-17-independent, and the severity of arthritis is dependent
on the production of IFN-gamma [19].
However, whether this is also the case in human arthritis
needs further clarification including the functional role of these
T cell subsets with focus on different stages of the disease.
Are IL-17+TNF+ memory T cells pathogenic Th17 cells
in early rheumatoid arthritis?
T cells and the cytokines IL-17A and TNF-alpha have been
shown to activate RA synovial fibroblast (RASF), resulting
in the expression of proinflammatory cytokines such as
IL-6 and IL-8, which are mediators of joint inflammation
[6, 7, 10, 60, 62, 73, 85]. In addition, an IL-17A-triggered
positive-feedback loop of IL-6 signaling in fibroblast has
been described in experimental arthritis and discussed
for human Th17-mediated autoimmune disorders [60, 72].
However, characterization of the T cell population that
activates RASF and responsible for IL-6 and IL-8 cytokine
induction has not been established. We identified IL-17+
TNF+Th17 cells in PBMC from treatment-naïve early RA
patients. These cells are identified as Th17 cells since they
express CCR6, IL-17F, IL-22, IL-26, RORc, CCL20, low
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T-bet, low FoxP3, and low IFN-gamma. Their functional
potential was examined using cocultures with early RASF.
CCR6+ (Th17) but not CCR6− (Th1) memory T cells were
potent inducers of IL-6, IL-8, and MMPs by the synovial
fibroblast in these cocultures. Of interest, also IL-17A
expression was increased in these cocultures with synovial
fibroblast indicating the induction of a proinflammatory
feedback loop. This Th17-RASF proinflammatory feedback
loop might be an important mechanism driving persistent
arthritis (Van Hamburg JP et al., unpublished observations;
Fig. 1). Blocking experiments revealed that both TNF and
IL-17A needed to be blocked for optimal suppressive
effect, indicating additional value of blocking Th17 activity
to anti-TNF neutralization in early RA (Van Hamburg JP et
al., unpublished observations).
These are the first data indicating potential pathogenicity
of Th17 cells in the human situation. Interestingly, data
from first clinical trials with anti-IL-17A antibody treatment
in psoriatic arthritis patients and RA patients looks
promising. Since additional neutralization of the Th17
cytokine IL-17A to TNF-alpha was needed to suppress
the mechanism that drives the proinflammatory feedback
loop in cocultures of cells from treatment-naïve early RA
patients, blocking Th17 activity in addition to anti-TNF in
early RA and potentially other Th17-mediated disorders
may be essential to reach the ultimate goals and that is (1)
to prevent the development of persistent and destructive
arthritis at the very early stage of the disease and (2) reach
permanent remission of the disease.
Does plasticity exist between Th1, Th17, and Treg
in arthritis?
Th17 cells appear to be associated with Treg cells, which
are indicated by the use of a common inducer, TGF-beta, an
overlapping chemokine receptor profile, and the expression
of the Th17-associated transcription factor RORgammat
[32, 87]. In mice, it has been shown that Treg cells can
be converted to IL-17-producing T cells [74, 95, 98].
Additionally, also human Treg cells, defined as CD4+
CD25highFoxP3+CD127-CD27+, were reported to differen-
tiate to IL-17-producing T cells. This was accompanied by an
upregulation of RORgammat and CCR6 expression [38].
Next to plasticity between Treg and Th17 cells new data
emerged that Th17 cells are closely related to Th1 cells. In
the mouse, differentiated Th17 cells responded rapidly in
vitro to IL-12, by upregulating the expression of IFN-gamma
and downregulating IL-17 expression. The development of
IFN-gamma-producing effector T cells from IL-17-producing
progenitor cells is inhibited in the presence of TGF-beta,
which is important for the maintenance of IL-17 expression
by Th17 polarized cells [49, 50, 58].
Recently, a role for epigenetic regulation of effector T cell
plasticity was found. For example, the gene encoding for
T-bet, the master regulator of Th1 differentiation, was found
to be in an active state, according to histone methylation
marks, in both Th17 and Treg cells. This implies that Th17
and Treg cells remain to have the potential to upregulate the
expression of T-bet and to differentiate towards Th1 cells [92].
Associations between T cell subsets such as Th17, Th1,
and Treg cells have been found in inflammation and
progression of RA. In joint inflammation of RA, high
levels of IL-17 can be found, and hardly any IFN-gamma
expression can be detected in the joint synovium [10, 76].
This was in line with studies in mice, which indicate
the importance for IL-17 in the induction of arthritis
[55]. In contrast, IFN-gamma cytokine levels were
detected in the joint synovium in later stages of RA, and
IFN-gamma expression was detected in joint infiltrating
CD4 T cells and in CD4 T cell clones, obtained from
inflamed synovium [1, 18, 64]. In line with these findings,
increased levels of IFN-gamma were detected in lymph
nodes and synovium at later time points when adjuvant
arthritis was induced in rats. In contrast, IL-17 was
induced shortly after initiation and declined in time [9].
In a 2-year predictive study, it became even evident that
IFN-gamma was playing a role in reducing joint progres-
sion. Inhibition of IFN-gamma in later disease was even
exacerbating the disease [37].
Next to Th1 cells, an inverse correlation between IL-17-
producing and FoxP3+ Treg cells has been identified. In
children with JIA, the balance between IL-17+ cells and
Treg cells may even be critical for the disease outcome [69].
In addition, Treg cells are present in higher numbers in
inflamed joints in patients with a mild RA phenotype,
compared to patients with a more severe disease [17, 78].
These observations indicated that plasticity between
Treg, Th1, and Th17 subsets exist and that differentiation
of these subsets was not completely restricted to separate
lineages. All together, these recent advances provide a
complete new concept of T cell plasticity that may be
relevant to the arthritis process (Fig. 1).
Do Th17 driving cytokines have any influence
on the pathogenicity of Th17 cells?
The role of IL-1, IL-6, IL-23, TGF-beta, and TNF-alpha in
the differentiation of mouse and human Th17 cells has been
reported [40]. However, the role of IL-23 in the effector
function of Th17 cells is not clearly understood. The
essential role for IL-23 in the pathogenic function of Th17
cells was shown in EAE [59]. In this experiment, Th17
cells, which were polarized under IL-23 polarizing con-
ditions, were potent inducers of EAE, while the pathogenic
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function in TGF-beta/IL-6-polarized Th17 cells was com-
pletely abrogated. A possible explanation for this discrep-
ancy could be the inhibited induction of IL-10 in the IL-23
polarized cells. Interestingly, TGF-beta/IL-6-polarized
Th17 cells modulated the induction of EAE by IL-23-
polarized Th17 cells [59]. These data indicate that IL-23 is
essential for the pathogenic function of Th17 cells. In line
with this, we have shown that IL-23 and TGF-beta/IL-6
differentially regulate T helper specific transcription factors
during Th17 development in autoimmune experimental
arthritis, which may explain the pathogenic potential of
IL-23 [66]. In CD4+ T cells from naïve and collagen-type II
immunized DBA/1 mice, IL-23 increased the expression of
IL-17A, IL-17F, and RORgammat. In contrast to TGF-beta/
IL-6, IL-23 inhibited the Th1 and regulatory T cell-specific
transcription factors T-bet and FoxP3 respectively [66].
In addition to IL-23, IL-1beta signaling in T cells has
been shown to induce a robust and durable primary and
secondary CD4 responses [5]. Mice defective in IL-1R1
signaling were resistant to EAE and exhibit a severe defect
in the generation of IL-17-producing T cells, suggesting
that IL-1 is important for mouse Th17 cell regulation in
vivo [83]. On the other hand, IL-1Ra-deficient mice
spontaneously developed chronic inflammatory arthropathy
which could be completely suppressed when crossing these
mice with IL-17A-deficient mice or TNF-alpha-deficient
mice [26, 67]. Moreover, IL-1 signaling regulated early
Th17 cell differentiation [11]. IL-1 receptor 1 (IL-1R1)
expression in T cells, which was induced by IL-6, was
necessary for the induction of experimental autoimmune
encephalomyelitis and for early Th17 cell differentiation in
vivo [11]. Moreover, IL-1 signaling in T cells was required
in dendritic cell-mediated Th17 cell differentiation from
naïve or regulatory precursors and IL-1 synergized with
IL-6 and IL-23 to regulate Th17 cell differentiation and
maintain cytokine expression in effector Th17 cells [11].
IL-1 regulated the expression of the transcription factors
IRF4 and RORgammat during Th17 cell differentiation [11].
Thus, similar to the human system, IL-1 plays a unique,
nonredundant role during murine Th17 cell polarization
[11], and its role in Th17 cell/Th17 cytokine regulation in
arthritis may be important [2, 56].
What is the functional role of the Th17 cytokines
IL-17F, IL-21, and IL-22 in arthritis?
IL-17F
Apart from the well-studied effects of IL-17A in arthritis
[33, 52, 55, 62], little is known about the specific role of
IL-17F in arthritis. It was shown that IL-17F is an important
regulator of inflammatory responses that seems to function
differently than IL-17A in immune responses and diseases
[97]. Although IL-17F has many biologically overlapping
effects with IL-17A, IL-17F is less potent, for example, in
activating synovial fibroblast [101]. IL-17F has been shown
to have cartilage destructive potential in vitro [28], IL-17F
played only marginal roles, if at all, in CIA and arthritis in
IL-1RA-deficient mice [31]. In contrast, both IL-17F and
IL-17Awere involved in host defense against mucoepithelial
infection by Staphylococcus aureus and Citrobacter
rodentium [31]. Of note, IL-17A was produced mainly in T
cells, whereas IL-17F was produced in T cells, innate
immune cells, and epithelial cells [31]. Further studies are
needed to clarify the role of IL-17F in arthritis and the
interaction of IL-17F with other Th17 cytokines.
IL-21
IL-21 was recently reported to play an important role in the
generation of Th17 cells. IL-21 was shown to be potently
induced by IL-6 [99]. IL-21 can be produced by Th17 cells
[39, 71] and can also be involved in Th17 polarization since
in the absence of IL-6, IL-21 in combination with TGF-beta
could function as an alternative signal for the induction of
Th17 cells [39].
In arthritis, IL-21R-deficient (IL-21R−/−)K/BxN mice
were completely refractory to the development of sponta-
neous arthritis [35]. These mice contain fewer CD4+ T cells
with a reduced proportion of homeostatically proliferating
cells, fewer follicular Th cells and, surprisingly, more Th17
cells than the control mice [35]. Moreover, these mice also
failed to develop IgG1+ memory B cells and autoantigen-
specific IgG1 antibodies secreting cells [35]. These data
suggest that IL-21 forms a positive-feedback autocrine loop
involving homeostatically activated CD4+ cells and is
essential in the development of autoimmune arthritis by
mechanisms dependent on follicular Th cells development,
autoreactive B cell maturation, and RANKL induction but
independent of Th17 cell function [35]. In line with this,
blocking IL-21 in CIA by in vivo administration of soluble
IL-21R-Fc fusion protein delayed the onset and progression
of arthritis [35]. In addition, in MLR/lpr mice, a spontane-
ous model for SLE, blocking IL-21 attenuated disease [24].
Genetic association of IL-21 polymorphisms with SLE has
been suggested [80]. In addition, a polymorphism within
IL-21R confers a risk for SLE [91]. Moreover, highly
suggestive evidence has been provided for IL-2/IL-21 loci
as a risk factor for RA [16]. These data suggest IL-21 to be
an interesting therapeutic target in arthritis.
IL-22
IL-22 is a cytokine belonging to the IL-10 super family [77]
and has been shown to act as an effector cytokine of the
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Th17 lineage [51]. IL-22 is primarily produced by activated
T cells and natural killer cells [93]. High levels of IL-22
were expressed both in the lining and the sublining layers
of RA synovial tissues [29]. The majority of IL-22-positive
cells were synovial fibroblasts and macrophages. IL-22R1
expression was also expressed in both the lining and the
sublining layers of RA synovial tissues [29]. IL-22
significantly increased proliferation of RASF and the
production of MCP-1 in vitro [29].
In line with other inflammatory models such as EAE
[43], we found that IL-23 is essential for IL-22 production in
polarized CD4+ T cells from naïve and type II collagen-
immunized DBA/1 mice [66]. IL-22-deficient mice were less
susceptible to CIA than wild type mice, as evidenced by
their decreased incidence of arthritis and decreased pannus
formation [23]. Remarkably, less severe CIA in IL-22-
deficient mice was associated with increased production of
CII-specific and total IgG antibodies, whereas cellular CII
responses were unchanged [23]. In vitro, IL-22 was found to
promote osteoclastogenesis [23]. Although these data sug-
gest a proinflammatory role of endogenous IL-22 in
arthritis, promoting osteoclastogenesis and regulating anti-
body production, the uncoupling between low incidence
and higher antibody production in IL-22-deficient mice
during CIA is unclear and needs further investigation.
In addition to IL-22 produced by Th17 cells, new
evidence exist that IL-22 can be produced by effector T
cells without IL-17A by a subset of human skin-homing
memory T cells [20, 86]. These so called “Th22” cells can
also be found in RA (Van Hamburg JP and Lubberts E,
unpublished observations); however, the function of these
cells in the pathogenesis of RA is unknown.
Modulation of Th17/Th17 cytokine activity in arthritis
Since Th17 cells and Th17 cytokines can have a proin-
flammatory effect in arthritis, it will be of interest to
understand how to regulate the activity of these cells/
cytokines. It has been shown that overexpression of the
Th2-specific transcription factor, GATA3, in T cells can
modulate Th17 cell differentiation and protects against
severe joint inflammation and bone erosion in experimental
arthritis [88]. Moreover, GATA3 overexpression resulted in
reduced gene expression of the Th17-associated transcrip-
tion factor RORgammat [88].
In addition, treatment of mice with CIA with anti-IL-6R
mAb on day0 markedly suppressed the induction of Th17
cells and arthritis development, but treatment with this
antibody on day14 failed to suppress both Th17 differen-
tiation and arthritis [22]. Of note, treatment of mice with
TNFR-Fc from day0 to day14 suppressed neither Th17
differentiation nor arthritis, but treatment from day21 to
day35 successfully ameliorated arthritis without inhibiting
Th17 induction [22]. This study indicate that the protective
effect of IL-6 blockade, but not TNF blockade in CIA,
correlated with the inhibition of Th17 differentiation and
suggest that IL-6 blockade in RA in human likely involve a
therapeutic mechanism distinct from that of TNF blockade
[22]. Moreover, Notley et al. [70] showed that TNF
blockade using TNFR-Fc fusion protein or anti-TNF
monoclonal antibody reduced collagen arthritis severity
but, unexpectedly, expanded populations of Th1 and Th17
cells, which were shown by adoptive transfer to be
pathogenic [70]). Th1 and Th17 cell populations were also
expanded in CII-immunized TNFR p55KO but not p75KO.
The expansion of Th1/Th17 cells was abrogated by
blockade of p40 [70]. However, although TNF blockade
increased numbers of Th1 an Th17 cells in lymph nodes, it
inhibited their accumulation in the joint, thereby providing
an explanation for the paradox that anti-TNF therapy
ameliorates arthritis despite increasing numbers of patho-
genic T cells [70].
Lai Kwan Lam et al. showed that local B cell-activating
factor (BAFF) gene silencing suppresses Th7 cell genera-
tion and ameliorates autoimmune arthritis [46]. TNF
superfamily member BAFF plays an important role in
humoral immunity and in autoimmune diseases, including
RA. Local BAFF gene targeting inhibited proinflammatory
cytokine expression, suppressed generation of plasma
cells and Th17 cells, and markedly ameliorated joint
pathology [46]. This study revealed a previously unrec-
ognized role for BAFF in promoting the expansion of
Th17 cells and demonstrated IL-17 as a crucial effector
cytokine for BAFF-mediated proinflammatory effects
during CIA development [46].
Apart from regulation of Th17 cells in experimental
mouse models for arthritis, Colin et al. showed modulatory
effects of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on
the memory Th17 activity in untreated early RA patients
[14]. 1,25-(OH)2D3 reduced the levels of IL-17A and IFN-
gamma and increased IL-4 in stimulated PBMC from
treatment-naïve early RA patients [14]. Interestingly, 1,25-
(OH)2D3, in contrast to dexamethasone, directly modulated
human Th17 polarization accompanied with suppression
of IL-17A, IL-17F, TNF-alpha, and IL-22 production by
FACS sorted memory T cells from these early RA patients
[14].
Conclusions
Ample evidence exist that Th17 cells are important in the
initiation of experimental autoimmune arthritis. The occur-
rence of this T cell subset seems to be dependent on the
stage of the disease and localization (systemically and/or at
Semin Immunopathol (2010) 32:43–53 49
site of inflammation). The functional role of Th17 cells and
their cytokines in human arthritis is still not known.
However, the first data from clinical trials using anti-IL-
17A antibody treatment in psoriatic arthritis and RA are
promising. Whether regulating Th17 cell activity or specific
combinations of Th17 cytokines will have additional value
compared to neutralizing IL-17A activity alone or TNF
alone needs to be elucidated.
The identification and diagnosis of RA early in the
disease course is becoming increasingly important because
early and intensive treatment has been demonstrated to
prevent joint damage, to preserve joint function, and to
improve work participation of patients [47, 48, 89].
Interestingly, the recognition of Th17 cells and Th17
cytokines in the very early stage of RA fits in the concept
that the IL-23/Th17 immune pathway may be important in
the development of this autoimmune disease [14, 52] (Van
Hamburg et al., unpublished observations). However, the
exact biological role of this immune pathway in the
development of arthritis needs further examination. In
addition, further understanding of the plasticity of T cell
subsets in the pathogenesis of chronic destructive arthritis
especially at different stages of the disease will be essential
to understand the T cell biology in RA. Moreover,
understanding of the effects of T cell plasticity on the
efficacy of different therapies may improve treatment.
Modulation of the Th17 pathway seems to be an interesting
approach alone or in addition to anti-TNF to reach the
ultimate goal of permanent remission or even to prevent the
development of this crippling disease.
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